Skip to main content

Articles

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Loretta Fala

Disparities in Cancer Care, Conference Highlights ASCO, Oncology

ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care

Wayne Kuznar

Conference Highlights ASCO, Lung Cancer, Oncology

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

Conference Highlights ASCO, Practice Management

Rapid Biosimilar Adoption Possible in Community Oncology Practice

Chase Doyle

Multiple Myeloma, Conference Highlights ASCO, Oncology

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO, Oncology

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO, Oncology

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO, Oncology

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Conference Highlights ASCO

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

FDA Approvals, Conference Highlights ASCO

Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma

Page 20 of 244
Results 191 - 200 of 2434